Drug intelligence / Profile preview

normal saline + tropisetron

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Intravenous

Overview

A pharmaceutical combination of normal saline (0.9% sodium chloride) and tropisetron hydrochloride used primarily in medical settings for preventing and treating nausea and vomiting, particularly in patients undergoing chemotherapy or surgery. Studies have shown this combination is compatible and stable, maintaining physical and chemical integrity for up to 48 hours when stored at both 4°C (with protection from light) and 25°C (without protection from light), retaining at least 97% of the initial tropisetron concentration. Tropisetron acts as a 5-HT3 receptor antagonist.

Other names: sodium chloride + tropisetron0.9% sodium chloride + tropisetrontropisetron in normal saline

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on normal saline + tropisetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on normal saline + tropisetron.

Explore the full profile